Cantargia: Video interview with CEO Göran Forsber

Research Interview



Redeye interviews Göran Forsberg about the new clinical development strategy for nadunolimab in pancreatic cancer with a controlled phase IIb trial instead of participating in Precision Promise.


Richard Ramanius

Sign up for free to continue

Already a member?

Sign in

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.